
浏览全部资源
扫码关注微信
400038 重庆,陆军军医大学(第三军医大学)第一附属医院泌尿外科,全军泌尿外科研究所
[ 陈志文,E-mail:zhiwen@tmmu.edu.cn CHEN Zhiwen, E-mail:zhiwen@tmmu.edu.cn
收稿:2019-03-23,
修回:2019-05-02,
纸质出版:2019-08-30
移动端阅览
张静琦, 周晓洲, 季惠翔, 等. 根治性前列腺癌切除术后首次血清PSA水平的影响因素分析[J]. 第三军医大学学报, 2019,41(16):1590-1595.
Jingqi ZHANG, Xiaozhou ZHOU, Huixiang JI, et al. Analysis of factors affecting first serum prostate specific antigen level after radical prostatectomy for prostate cancer[J]. Journal of Third Military Medical University, 2019, 41(16): 1590-1595.
张静琦, 周晓洲, 季惠翔, 等. 根治性前列腺癌切除术后首次血清PSA水平的影响因素分析[J]. 第三军医大学学报, 2019,41(16):1590-1595. DOI: 10.16016/j.1000-5404.201903200.
Jingqi ZHANG, Xiaozhou ZHOU, Huixiang JI, et al. Analysis of factors affecting first serum prostate specific antigen level after radical prostatectomy for prostate cancer[J]. Journal of Third Military Medical University, 2019, 41(16): 1590-1595. DOI: 10.16016/j.1000-5404.201903200.
目的
2
分析影响根治性前列腺癌切除术(radical prostatectomy,RP)后首次血清前列腺特异性抗原(prostate specific antigen,PSA)水平的因素。
方法
2
回顾性收集2014年1月至2018年5月本科行RP的251例患者的临床病理资料,按照术后6~8周首次血清PSA值是否达到生化复发水平,以0.2 ng/mL为分界点将患者分为PSA < 0.2 ng/mL组和PSA≥0.2 ng/mL组,针对两组患者数据进行单因素分析及多因素Logistic回归分析,筛选出影响RP后首次PSA水平的因素。
结果
2
① 251例前列腺癌患者:两组患者在BMI、术前有无电切、术前PSA、术后Gleason评分、病理T分期、有无淋巴结清扫、淋巴结清扫数量差异均有统计学意义(
P
<
0.05);多因素Logistic回归分析结果表明BMI、术前PSA、术后Gleason评分、病理T分期为影响术后首次血清PSA水平的独立危险因素;②153例淋巴结清扫的前列腺癌患者:两组在BMI、术前PSA、术后Gleason评分、病理T分期、淋巴结是否阳性、阳性淋巴结数量差异均有统计学意义(
P
<
0.05);多因素Logistic回归分析结果表明术前PSA、淋巴结阳性为影响术后首次血清PSA水平的独立危险因素。
结论
2
BMI、术前PSA、术后Gleason评分、病理T分期是影响前列腺癌患者术后首次血清PSA水平的独立危险因素;术前PSA和淋巴结阳性是影响淋巴结清扫的前列腺癌患者术后首次血清PSA水平的独立危险因素。
Objective
2
To analyze the factors affecting postoperative first serum prostate specific antigen (PSA) level at 6 weeks in patients receiving radical prostatectomy (RP) for prostate cancer.
Methods
2
The clinicopathological data were collected retrospectively from 251 patients undergoing RP for prostate cancer in our department between January
2014 and May
2018. According to postoperative first serum PSA levels at 6-8 weeks for assessing biochemical recurrence (with 0.2 ng/mL as the cut-off PSA level)
the patients were divided into PSA < 0.2 ng/mL group and PSA≥0.2 ng/mL group
and univariate analysis and multivariate Logistic regression analysis was performed to identify the factors affecting first serum PSA level after RP.
Results
2
The two groups of patients with prostate cancer showed significant differences in BMI
history of preoperative electric resection
preoperative PSA level
postoperative Gleason score
pathological T staging
lymph node dissection
and the number of dissected lymph nodes (
P
<
0.05). The results of multivariate Logistic regression analysis showed that BMI
preoperative PSA level
postoperative Gleason score and pathological T staging were all independent risk factors affecting postoperative first serum PSA level. In the 153 patients with lymph node dissection
BMI
preoperative PSA level
postoperative Gleason score
pathological T staging
lymph node positivity and the number of positive lymph nodes differed significantly between the patients with postoperative PSA level
<
0.2 ng/mL at 6 weeks and those with higher PSA levels (
P
<
0.05). Multivariate Logistic regression analysis showed that preoperative PSA level and lymph node positivity were independent risk factors that affected the postoperative first serum PSA level.
Conclusion
2
BMI
preoperative PSA level
postoperative Gleason score and pathologic T staging are all independent risk factors affecting the postoperative first serum PSA level in prostate cancer patients; In patients with lymph node dissection
preoperative PSA level and lymph node positivity are independent risk factors affecting the postoperative first serum PSA level.
CHEN W, ZHENG R, BAADE P D, et al . Cancer statistics in China, 2015[J ] . Cancer J Clin, 2016, 66(2): 115-132. DOI:10.3322/caac.21338.
叶定伟, 朱耀.中国前列腺癌的流行病学概述和启示[J].中华外科杂志, 2015, 53(4): 249-252. DOI: 10.3760/cma.j.issn.0529-5815.2015.04.003.
YE D W, ZHU Y. Epidemiology of prostate cancer in China: an overview and clinical implication[J]. Chin J Surg, 2015, 53(4): 249-252.DOI:10.3760/cma.j.issn.0529-5815.2015.04.003.
马春光, 叶定伟, 李长岭, 等.前列腺癌的流行病学特征及晚期一线内分泌治疗分析[J].中华外科杂志, 2008, 46(12): 921-925. DOI: 10.3321/j.issn:0529-5815.2008.12.012.
MA C G, YE D W, LI C L, et al . Epidemiology of prostate cancer from three centers and analysis of the first-fine hormonal therapy for the advanced disease[J ] . Chin J Surg, 2008, 46(12): 921-925. DOI: 10.3321/j.issn:0529-5815.2008.12.012.
BRAWLEY O W, GANSLER T. Introducing the 2010 American cancer society prostate cancer screening guideline[J]. Cancer J Clin, 2010, 60(2): 68-69. DOI: 10.3322/caac.20067.
[MOHLER J L, ARMSTRONG A J, BAHNSON R R, et al . National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology: prostate cancer (Version 1.2017)[EB/OL ] . [2016-12-16 ] . http://www.nccn.org/patients http://www.nccn.org/patients ..
中国抗癌协会泌尿男生殖系肿瘤专业委员会微创学组.中国前列腺癌外科治疗专家共识[J].中华外科杂志, 2017, 55(10): 721-724.DOI: 10.3760/cma.j.issn.0529-5815.2017.10.001.
Minimally Invasive Surgery Group of Chinese Anti Cancer Association Genitourinary Oncology Committee. Consensus of Chinese experts on prostate neoplasms surgical treatment[J]. Chin J Surg, 2017, 55(10): 721-724. DOI: 10.3760/cma.j.issn. 0529-5815.2017.10. 001.
CAO Y, MA J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: A systematic review and meta-analysis[J]. Cancer Prev Res (Phila), 2011, 4(4): 486-501. DOI:10.1158/1940-6207.CAPR-10-0229.
MØLLER H, ROSWALL N, VAN HEMELRIJCK M, et al . Prostate cancer incidence, clinical stage and survival in relation to obesity: A prospective cohort study in Denmark[J ] . Int J Cancer, 2015, 136(8): 1940-1947. DOI: 10.1002/ijc.29238.
VIDAL A C, HOWARD L E, SUN S X, et al . Obesity and prostate cancer-specific mortality after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH)database[J ] . Prostate Cancer Prostatic Dis, 2017, 20(1): 72-78. DOI: 10.1038/pcan.2016.47.
BAI P D, HU M B, XU H, et al . Body mass index is associated with higher Gleason score and biochemical recurrence risk following radical prostatectomy in Chinese men: A retrospective cohort study and meta-analysis[J ] . World J Surg Oncol, 2015, 13: 311. DOI: 10.1186/s12957-015-0725-0.
THOMPSON R H, BLUTE M L, SLEZAK J M, et al . Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era?[J ] . J Urol, 2007, 178(2): 459-463; discussion 463. DOI: 10.1016/j.juro.2007.03.124.
RITCH C R, YOU C C, MAY A T, et al . Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer[J ] . Urology, 2014, 83(6): 1309-1315. DOI: 10.1016/j.urology.2014.02.023..
BARRY DELONGCHAMPS N, PEYROMAURE M, KPATCHA F, et al . PT3N0 prostate cancer treated with radical prostatectomy as sole treatment: Oncological results and predictive factors of recurrence[J ] . Prog Urol, 2012, 22(2): 100-105. DOI: 10.1016/j.purol.2011.08.041.
戴波, 常坤, 孔蕴毅, 等.根治性前列腺切除术后患者生化复发的危险因素分析[J].中华外科杂志, 2015, 53(4): 261-265. DOI: 10.3760/cma.j.issn.0529-5815.2015.04.006.
DAI B, CHANG K, KONG Y Y, et al . Analysis of biochemica l recurrence following radical prostatectomy[J ] . Chin J Surg, 2015, 53(4): 261-265. DOI: 10.3760/cma.j.issn. 0529-5815.2015.04.006.
DIAZ M, PEABODY J O, KAPOOR V, et al . Oncologic outcomes at 10 years following robotic radical prostatectomy[J ] . Eur Urol, 2015, 67(6): 1168-1176. DOI: 10.1016/j.eururo.2014.06.025.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621